<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00469820</url>
  </required_header>
  <id_info>
    <org_study_id>J06118 CDR0000543531</org_study_id>
    <secondary_id>P01CA015396</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J06118</secondary_id>
    <nct_id>NCT00469820</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant</brief_title>
  <official_title>Posttransplant Immunotherapy With Donor Lymphocyte Infusions and Autologous Tumor Vaccines After HLA-Matched Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from the patient's cancer cells may help the body build an effective&#xD;
      immune response to kill cancer cells. Giving vaccine therapy together with donor lymphocyte&#xD;
      infusion after a stem cell transplant from the patient's brother or sister may kill any&#xD;
      cancer cells that remain after transplant.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying the side effects, best dose, and how well vaccine&#xD;
      therapy with or without donor lymphocyte infusion works in treating patients with acute&#xD;
      myeloid leukemia, acute lymphoblastic leukemia, or multiple myeloma undergoing donor stem&#xD;
      cell transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine time to relapse and overall survival of patients with high-risk acute myeloid&#xD;
           leukemia, acute lymphoblastic leukemia, or multiple myeloma treated with autologous&#xD;
           tumor cell vaccine with or without donor lymphocyte infusion after HLA-matched related&#xD;
           sibling nonmyeloablative hematopoietic stem cell transplantation.&#xD;
&#xD;
        -  Evaluate the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of donor lymphocyte infusions in these patients.&#xD;
&#xD;
      OUTLINE: Patients undergo collection of tumor cells for production of the cancer cell vaccine&#xD;
      and then undergo HLA-matched related sibling nonmyeloablative hematopoietic stem cell&#xD;
      transplantation (HSCT). Patients then receive cancer cell vaccine with or without donor&#xD;
      lymphocyte infusion. The donor lymphocytes are obtained from the same relative who donated&#xD;
      stem cells for the HSCT.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to relapse</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability, in terms of incidence of graft-versus-host disease and local/systemic toxicities</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose of donor lymphocytes</measure>
  </primary_outcome>
  <enrollment type="Actual">1</enrollment>
  <condition>Leukemia</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous tumor cell vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>peripheral blood lymphocyte therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  Acute myeloid leukemia (AML), meeting any of the following criteria:&#xD;
&#xD;
                    -  Relapsed disease&#xD;
&#xD;
                    -  AML arising from myelodysplastic syndromes&#xD;
&#xD;
                    -  Primary refractory disease&#xD;
&#xD;
                    -  De novo AML with high-risk features&#xD;
&#xD;
               -  Acute lymphoblastic leukemia (ALL), meeting any of the following criteria:&#xD;
&#xD;
                    -  De novo ALL that is Philadelphia chromosome positive or with t(4,11)&#xD;
                       cytogenetic features&#xD;
&#xD;
                    -  Relapsed disease&#xD;
&#xD;
               -  Multiple myeloma (in need of treatment)&#xD;
&#xD;
          -  Planning to undergo HLA-matched related sibling nonmyeloablative hematopoietic stem&#xD;
             cell transplantation&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol A. Huff, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2007</study_first_posted>
  <last_update_submitted>March 20, 2014</last_update_submitted>
  <last_update_submitted_qc>March 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2014</last_update_posted>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

